Bio-Rad Laboratories, Inc has launched a range of recombinant monoclonal anti-ranibizumab antibodies that are highly specific for the monoclonal antibody drug ranibizumab (Lucentis) or the complex of ranibizumab with its target, vascular endothelial growth factor A (VEGF-A).
Ranibizumab is used for the treatment of wet age-related macular degeneration (AMD), a common form of age-related vision loss, and for macular edema and diabetic retinopathy. The anti-ranibizumab antibodies are inhibitory, non-inhibitory, and drug-target-complex-specific antibodies designed for use in pharmacokinetic (PK) and immunogenicity assays for ranibizumab and its biosimilars.
“We are excited to introduce four anti-ranibizumab antibodies that are highly specific for ranibizumab or the ranibizumab-VEGF-A complex,” said Amanda Turner, Bio-Rad Product Manager, Life Science Group. “Ranibizumab is a Fab fragment drug and is present at very low levels in patient samples, which presents challenges for PK assay design and sensitivity. The high-affinity ranibizumab-VEGF-complex-specific antibody is unique to Bio-Rad and overcomes those challenges by enabling the development of a PK antigen capture assay to measure free drug.”
Bio-Rad’s anti-idiotypic antibodies are generated using Human Combinatorial Antibody Library (HuCAL) and CysDisplay, a proprietary method of phage display with guided selection methods to obtain highly targeted reagents. Bio-Rad says the recombinant production method also ensures a consistent and secure supply.
The antibodies are approved for in-vitro research and for commercial applications of in-vitro testing services that support preclinical and clinical drug and biosimilar development and patient monitoring.
For further information about Bio-Rad’s anti-ranibizumab antibodies visit www.bio-rad-antibodies.com/anti-ranibizumab-antibody-lucentis.html
Latest from Tom Mulligan
- SGS’s first malaria human challenge trial will take place in Belgium this month
- TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products
- Horizon Discovery extends CRISPR Screening Service to primary human T cells
- TrakCel and The Quick Life Science Group partner on supply chain IT solution for cell and gene therapies
- Almac Group extends personalised cancer vaccine production facilities
- Cobra Biologics appoints Dr Darrell Sleep as Director of Innovation
- Phico Therapeutics appoints financial director and two non-executive directors
- Evonetix appoints Stephanie Brooking as Head of Product Management
- Bio-Rad publishes new findings on generation and characterisation of drug-target-complex-specific antibodies
- Expedeon licenses Lightning-Link rapid biotinylation technology to Cell Guidance Systems